Region: International

The five hub-and-spokes models transforming pharma IP commercialisation

Several approaches have emerged under this banner, each offering advantages and disadvantages

15 August 2022

What made Colombia an attractive venue for Ericsson in its patent battle with Apple

The Swedish company has been a prolific filer in a country whose judicial processes strongly favour plaintiffs

11 August 2022

Pfizer and Amgen fight to avoid patent cliff falls in multi-billion dollar buying sprees

With significant revenue drop-offs from existing branded products set to decline steeply in the second half of this decade, major portfolio acquisitions are a priority for both companies

10 August 2022

Sanofi farms out more IP as part of “play to win” strategy

The French company is one of several big pharmas to have offloaded deprioritised drugs in recent months

29 July 2022

WIPO-USPTO SEP arbitration agreement sparks market scepticism

Moves to encourage parties away from the courts and towards ADR are welcome, say observers, but a lot more is needed for it to happen

27 July 2022

Royalty Pharma spends $1.3 billion in latest drug revenue rights purchase

Royalty transactions are an increasingly attractive means of cashing in on life sciences innovation, and the returns can be significant

15 July 2022

Breaking: Avanci to hike 4G licence rate

Connected vehicles platform ditches its well-known $15-per-vehicle price tag

12 July 2022

Toyota and Honda ramp up patent filings as wireless technologies become litigation battlefield

London-based firm Mathys & Squire’s research reveals that Japan is the most popular patenting jurisdiction for auto OEMs

08 July 2022

Nokia wins German SEP injunction in major victory against Oppo

The order is the second recent victory for the Finnish company in its global licensing dispute with the Chinese handset maker

06 July 2022

Pfizer to commercialise its IP with the help of trailblazing Roivant approach

The partnership is aimed at helping the pharma giant to moentise deprioritised IP in the autoimmune space

04 July 2022